ResMed Accounts payable and other current liabilities increased by 875.8% to $103.88M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 64.6%, from $63.09M to $103.88M. Over 3 years (FY 2021 to FY 2025), Accounts payable and other current liabilities shows a downward trend with a -24.4% CAGR.
An increase suggests the company is effectively utilizing supplier credit to preserve cash, while a decrease indicates faster payment cycles.
Reflects the net change in obligations to suppliers and other accrued expenses that have been incurred but not yet paid....
A standard working capital metric used to evaluate cash management strategies across all sectors.
other_increase_decrease_in_accounts_payable_and_accrued__ecb401| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $52.59M | -$293.30M | -$12.39M | $27.72M | $8.04M | -$17.27M | $40.24M | $330.00K | -$1.02M | -$34.37M | $35.49M | $121.98M | -$25.44M | $4.22M | $63.09M | $49.09M | $7.64M | $10.65M | $103.88M |
| QoQ Change | — | -657.7% | +95.8% | +323.7% | -71.0% | -314.8% | +333.0% | -99.2% | -408.5% | <-999% | +203.2% | +243.7% | -120.9% | +116.6% | >999% | -22.2% | -84.4% | +39.4% | +875.8% |
| YoY Change | — | — | — | — | +102.7% | -39.4% | +45.2% | — | -112.7% | -99.0% | -11.8% | >999% | <-999% | +112.3% | +77.8% | -59.8% | +130.0% | +152.3% | +64.6% |